Sodium Iodide I 123 Diagnostic-Capsules for Oral Administration

Manufacturer
Cardinal Health 418, Inc
Effective date
2018-04-17
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
3
Source
full-release
Hydrated at
2026-05-31 20:25:38

Label at a glance#

ProductSodium Iodide I 123
Active ingredientSODIUM IODIDE I-123
Label structure11 sections

Dosage and administration

The recommended oral dose for the average patient (70 kg) is 3.7 to 14.8 MBq (100-400 µCi). The lower part of the dosage range 3.7 MBq (100 µCi) is recommended for uptake studies alone, and the higher part 14.8 MBq (400 µCi) for thyroid imaging. The determination of I 123 concentration in the thyroid gland may be initiated at six hours after administering the dose and should be measured in accordance with standard...

Label contents#

Full prescribing information#

DESCRIPTION

DESCRIPTION SECTION

Sodium Iodide I 123 (Na123I) for diagnostic use is supplied in capsules for oral administration. The capsules are available in strengths of 3.7 and 7.4 megabecquerels (MBq) (100 and 200 μCi) I 123 at time of calibration. Each capsule contains 0.3 µg - 3 µg Sodium Thiosulfate as a stabilizer.

The radionuclidic composition at calibration is not less than 97.0 percent I 123, not more than 2.9 percent I 125 and not more than 0.1 percent all others (I 121 or Te 121.) The radionuclidic composition at expiration time is not less than 87.2 percent I 123, not more than 12.4 percent I 125 and not more than 0.4 percent all others. The ratio of the concentration of I 123 and I 125 changes with time. Graph 1 shows the maximum concentration of each as a function of time.

Graph 1 Radionuclidic Concentration of I 123 and I 125
Graph 1 Radionuclidic Concentration of I 123 and I 125

Physical Characteristics

SPL UNCLASSIFIED SECTION

Sodium Iodide I 123 decays by electron capture with a physical half-life of 13.2 hours. The photon that is useful for detection and imaging studies is listed in Table 1.

Table 1 Principal Radiation Emission Data1
1 Kocher, David C., Radioactive Decay Data Tables, DOE/TIC-11026, 122, (1981)

Radiation

Mean %/Disintegration

Mean Energy
(keV)

Gamma-2

83.4

159

External Radiation

SPL UNCLASSIFIED SECTION

The specific gamma ray constant for I 123 is 1.6 R/hr-mCi at 1 cm. The first half value thickness of lead (Pb) for I 123 is 0.005 cm. A range of values for the relative attenuation of the radiation emitted by this radionuclide that results from the interposition of various thicknesses of Pb is shown in Table 2. For example, the use of 1.63 cm of lead will decrease the external radiation exposure by a factor of about 1,000.

Table 2 Radiation Attenuation by Lead Shielding2
2 Shleien, Bernard, The Health Physics and Radiological Health Handbook, Table 6.1.2, 169, (1992)

Shield Thickness (Pb), cm

Coefficient of Attenuation

0.036

0.5

0.120

10-1

0.240

10-2

0.358

10-3

0.477

10-4

Note that these estimates of attenuation do not take into consideration the presence of contaminants.

To correct for physical decay of I 123, the fractions that remain at selected intervals after the time of calibration are shown in Table 3.

Table 3 Sodium Iodide I 123 Decay Chart: Half-Life 13.2 Hours
*Time of Calibration

Hours

Fraction Remaining

Hours

Fraction Remaining

0*

1.000

18

.389

3

.854

21

.332

6

.730

24

.284

9

.623

27

.242

12

.535

30

.207

15

.455

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

Sodium Iodide I 123 is readily absorbed from the upper gastrointestinal tract. Following absorption, the iodide is distributed primarily within the extracellular fluid of the body. It is trapped and organically bound by the thyroid and concentrated by the stomach, choroid plexus and salivary glands. It is excreted by the kidneys.

The fraction of the administered dose which is accumulated in the thyroid gland may be a measure of thyroid function in the absence of unusually high or low iodine intake or administration of certain drugs which influence iodine accumulation by the thyroid gland. Accordingly, the patient should be questioned carefully regarding previous medication and/or procedures involving radiographic media. Normal subjects can accumulate approximately 10-50% of the administered iodine dose in the thyroid gland, however, the normal and abnormal ranges are established by individual physician's criteria. The mapping (imaging) of Sodium Iodide I 123 distribution in the thyroid gland may provide useful information concerning thyroid anatomy and definition of normal and/or abnormal functioning of tissue within the gland.

INDICATION AND USE

INDICATIONS & USAGE SECTION

Administration of Sodium Iodide I 123 is indicated as a diagnostic procedure to be used in evaluating thyroid function and/or morphology.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

To date there are no known contraindications to the use of Sodium Iodide I 123 capsules.

WARNINGS

WARNINGS SECTION

Females of childbearing age and children under 18 should not be studied unless the benefits anticipated from the performance of the test outweigh the possible risk of exposure to the amount of ionizing radiation associated with the test.

PRECAUTIONS

PRECAUTIONS SECTION

General

GENERAL PRECAUTIONS SECTION

The contents of the capsule are radioactive. Adequate shielding of the preparation must be maintained at all times.

Do not use after the expiration time and date (30 hours after calibration time) stated on the label.

The prescribed Sodium Iodide I 123 dose should be administered as soon as practical from the time of receipt of product (i.e., as close to calibration time as possible) in order to minimize the fraction of radiation exposure due to relative increase of radionuclidic contaminants with time.

Sodium Iodide I 123, as well as other radioactive drugs, must be handled with care and appropriate safety measures should be used to minimize radiation exposure to clinical personnel. Care should also be taken to minimize radiation exposure to the patient consistent with proper patient management.

Radiopharmaceuticals should be used only by physicians who are qualified by training and experience in the safe use and handling of radionuclides and whose experience and training have been approved by the appropriate government agency authorized to license the use of radionuclides.

Carcinogenesis, Mutagenesis, Impairment of Fertility

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

No long-term animal studies have been performed to evaluate carcinogenic potential, mutagenic potential, or whether Sodium Iodide I 123 affects fertility in males or females.

Pregnancy

SPL UNCLASSIFIED SECTION

Animal reproduction studies have not been conducted with this drug. It is also not known whether Sodium Iodide I 123 can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. Sodium Iodide I 123 should be given to a pregnant woman only if clearly needed.

Ideally examinations using radiopharmaceuticals, especially those elective in nature, in women of childbearing capability should be performed during the first few (approximately ten) days following the onset of menses.

Nursing Mothers

NURSING MOTHERS SECTION

Since I 123 is excreted in human milk, formula-feeding should be substituted for breast-feeding if the agent must be administered to the mother during lactation.

Pediatric Use

PEDIATRIC USE SECTION

Safety and effectiveness in children have not been established.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

Although rare, reactions associated with the administration of Sodium Iodide isotopes for diagnostic use include, in decreasing order of frequency, nausea, vomiting, chest pain, tachycardia, itching skin, rash and hives.

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

The recommended oral dose for the average patient (70 kg) is 3.7 to 14.8 MBq (100-400 µCi). The lower part of the dosage range 3.7 MBq (100 µCi) is recommended for uptake studies alone, and the higher part 14.8 MBq (400 µCi) for thyroid imaging. The determination of I 123 concentration in the thyroid gland may be initiated at six hours after administering the dose and should be measured in accordance with standardized procedures.

The patient dose should be measured by a suitable radioactive calibration system immediately prior to administration. The capsules can be utilized up to thirty (30) hours after calibration time and date. Thereafter, discard the capsules in accordance with standard safety procedures. The user should wear waterproof gloves at all times when handling the capsules or container.

Radiation Dosimetry

SPL UNCLASSIFIED SECTION

The estimated absorbed radiation doses to several organs of an average patient (70 kg) from oral administration of the maximum dose of 14.8 MBq (400 µCi) of I 123 are shown in Table 4 for thyroid uptakes of 5, 15, and 25%. For comparison at these three values of thyroid uptake, the estimated radiation doses from doses of 3.7 MBq (100 µCi) I 131, also used as thyroid imaging agent, are also included.

Table 4 Radiation Dose Estimates as a Function of Maximum Thyroid Uptake for I 123* Sodium Iodide At Time of Calibration and Expiry Compared to I 131
*Concentration at Time of Calibration: 97% I 123, 2.9% I 125, 0.1% Te 121
Concentration at Time of Expiry: 87.2% I 123, 12.4% I 125, 0.4% Te 121
All Iodine Kinetics treated as in MIRD Dose Estimate Report 5. Bladder voiding interval, 4.8 hours.
Tellurium 121 dosimetry taken from ICRP 30.

Target Organ

Maximum
Thyroid
Uptake (%)

Estimated Radiation Absorbed Doses

I 123
mGy/14.8 MBq
(rads/400 µCi)

I 131
mGy/3.7 MBq
(rads/100 µCi)

TOC

TOE

Thyroid

5

25

(2.5)

75

(7.5)

260

(26)

15

77

(7.7)

230

(23)

780

(78)

25

130

(13)

410

(41)

1300

(130)

Liver

5

0.089

(0.0089)

0.13

(0.013)

0.16

(0.016)

15

0.10

(0.010)

0.18

(0.018)

0.28

(0.028)

25

0.11

(0.011)

0.24

(0.024)

0.41

(0.041)

Ovaries

5

0.18

(0.018)

0.19

(0.019)

0.18

(0.018)

15

0.17

(0.017)

0.18

(0.018)

0.18

(0.018)

25

0.16

(0.016)

0.18

(0.018)

0.17

(0.017)

Red Marrow

5

0.12

(0.012)

0.16

(0.016)

0.15

(0.015)

15

0.12

(0.012)

0.18

(0.018)

0.21

(0.021)

25

0.13

(0.013)

0.19

(0.019)

0.27

(0.027)

Stomach Wall

5

0.96

(0.096)

0.98

(0.098)

1.7

(0.17)

15

0.89

(0.089)

0.91

(0.091)

1.5

(0.15)

25

0.82

(0.082)

0.85

(0.085)

1.4

(0.14)

Small Intestine

5

0.70

(0.070)

0.71

(0.071)

1.2

(0.12)

15

0.65

(0.065)

0.67

(0.067)

1.1

(0.11)

25

0.60

(0.060)

0.62

(0.062)

0.99

(0.099)

Testes

5

0.076

(0.0076)

0.089

(0.0089)

0.12

(0.012)

15

0.072

(0.0072)

0.087

(0.0087)

0.12

(0.012)

25

0.068

(0.0068)

0.085

(0.0085)

0.12

(0.012)

Bladder

5

1.7

(0.17)

1.7

(0.17)

2.9

(0.29)

15

1.6

(0.16)

1.6

(0.16)

2.7

(0.27)

25

1.4

(0.14)

1.5

(0.15)

2.4

(0.24)

Skeleton

5

0.11

(0.011)

0.16

(0.016)

0.12

(0.012)

15

0.12

(0.012)

0.18

(0.018)

0.18

(0.018)

25

0.14

(0.014)

0.21

(0.021)

0.24

(0.024)

Total Body

5

0.11

(0.011)

0.16

(0.016)

0.24

(0.024)

15

0.14

(0.014)

0.25

(0.025)

0.47

(0.047)

25

0.17

(0.017)

0.35

(0.035)

0.70

(0.070)

HOW SUPPLIED

HOW SUPPLIED SECTION

Sodium Iodide I 123 is supplied as capsules for oral administration in strengths of 3.7 MBq (100 µCi) and 7.4 MBq (200 µCi) at time of calibration. Each gelatin capsule contains 0.45 - 0.65 g of sucrose. The capsules are packaged in plastic vials containing either one or five capsules of a single strength per vial. The plastic vial is packaged in a lead shield with a label identical to that affixed to the plastic vial. A package insert is supplied with each lead shield.

The -I (Iodine) content for a 100 µCi capsule is 5.2 ng and the -I content for a 200 µCi capsule is 10.4 ng at TOC.

Dispense and preserve capsules in well-closed containers that are adequately shielded. Store at room temperature, below 86°F.

The contents of the capsules are radioactive. Adequate shielding and handling precautions must be maintained.

THIS PACKAGE INSERT ISSUED APRIL 2018

CardinalHealth
Denver, CO 80011     (303) 343-6800

Sodium Iodide I 123
1-020-16

PRINCIPAL DISPLAY PANEL - 100 µCi CAPSULE

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

100 µCi Capsule
100 µCi Capsule

CardinalHealth
Denver, CO 80011

NUMBER OF CAPSULES: 1

ASSAY: 3.7 MBq (100 uCi) Per Capsule

TOTAL ACTIVITY: 3.7 MBq (100 uCi)

CALIB. DATE:

CALIB. TIME:

BATCH NO.:

SODIUM IODIDE I 123
3.7 MBq (100 uCi) CAPSULES
DIAGNOSTIC
FOR ORAL USE ONLY

EXPIRATION: 30 hours from the Date
and Time of Calibration.

Rx only

READ PACKAGE INSERT
FOR DIRECTIONS FOR USE.

Iodine 123 Radioactive
Half-life 13.2 hours,
carrier free.
Calculate correct
dosage from Date and
Time of Calibration

STORE AT ROOM TEMPERATURE (BELOW 86° F)

CAUTION RADIOACTIVE MATERIAL

1-001-10

PRINCIPAL DISPLAY PANEL - 200 µCi CAPSULE

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

200 µCi Capsule
200 µCi Capsule

CardinalHealth
Denver, CO 80011

NUMBER OF CAPSULES: 1

ASSAY: 7.4 MBq (200 uCi) Per Capsule

TOTAL ACTIVITY: 7.4 MBq (200 uCi)

CALIB. DATE:

CALIB. TIME:

BATCH NO.:

SODIUM IODIDE I 123
7.4 MBq (200 uCi) CAPSULES
DIAGNOSTIC
FOR ORAL USE ONLY

EXPIRATION: 30 hours from the Date
and Time of Calibration.

Rx only

READ PACKAGE INSERT
FOR DIRECTIONS FOR USE.

Iodine 123 Radioactive
Half-life 13.2 hours,
carrier free.
Calculate correct
dosage from Date and
Time of Calibration

STORE AT ROOM TEMPERATURE (BELOW 86° F)

CAUTION RADIOACTIVE MATERIAL

1-002-10

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
4073022c-5d5d-48f5-82ed-091ad146a4b2Product name120171211
9ffbd0ae-0bce-c086-b707-f0da5f8cd7c5Product name120150828

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
48815-1001-1Sodium Iodide I 1231 in 1 VIAL, PLASTICCAPSULE, GELATIN COATED13
48815-1001-1Sodium Iodide I 1231 in 1 CANCAPSULE, GELATIN COATED13
48815-1001-5Sodium Iodide I 1235 in 1 VIAL, PLASTICCAPSULE, GELATIN COATED53
48815-1001-5Sodium Iodide I 1231 in 1 CANCAPSULE, GELATIN COATED13
48815-1002-1Sodium Iodide I 1231 in 1 VIAL, PLASTICCAPSULE, GELATIN COATED13
48815-1002-1Sodium Iodide I 1231 in 1 CANCAPSULE, GELATIN COATED13
48815-1002-5Sodium Iodide I 1235 in 1 VIAL, PLASTICCAPSULE, GELATIN COATED53
48815-1002-5Sodium Iodide I 1231 in 1 CANCAPSULE, GELATIN COATED13

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
48815-1001SODIUM IODIDE I 123 CAPSULE, GELATIN COATED [CARDINAL HEALTH 418, INC]3Current NDC, Legacy NDC, 4 package rows20180418_50415c27-1928-4307-b1dc-648f47edf65d.zip
48815-1002SODIUM IODIDE I 123 CAPSULE, GELATIN COATED [CARDINAL HEALTH 418, INC]3Current NDC, Legacy NDC, 4 package rows20180418_50415c27-1928-4307-b1dc-648f47edf65d.zip

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
48815-1001-1EA - Each48815-10015ae46c33-3f92-4256-b2ee-c5ac1220218512020-01-03
48815-1001-5EA - Each48815-1001fdd5924c-4296-4a96-b3cc-8cfa3cda2a3512020-01-03
48815-1002-1EA - Each48815-10023df0358a-1d23-4aad-81fd-028f768b27eb12020-01-03
48815-1002-5EA - Each48815-1002eb7ae9ac-91a7-497a-9519-de1e3896610212020-01-03

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIISPL versionUploaded
SODIUM IODIDE I-123ACTIVE INGREDIENT29UKX3A6162
IODIDE ION I-123ACTIVE MOIETY98QPV8670C2
SODIUM THIOSULFATEINACTIVE INGREDIENTHX1032V43M2
SUCROSEINACTIVE INGREDIENTC151H8M5542

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 5 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
48815-100148815-1001-1, 48815-1001-5
48815-100248815-1002-1, 48815-1002-5

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 6 matching rows.

Source Document#

Source XML

Inactive ingredient matches#

Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.

Inactive ingredient links page 1 of 4 · 210 matching rows.

DailyMed ingredient, IID ingredient, UNII table
DailyMed ingredientIID ingredientUNIIDosage form / routePotencyMaximum daily exposureMatch
SODIUM THIOSULFATESODIUM THIOSULFATEHX1032V43MSOLUTION / ORAL22 mg/1mlExact identifier — unii+route
24 equally ranked IID candidates
SUCROSESUCROSEC151H8M554GRANULE, FOR SUSPENSION, EXTENDED RELEASE / ORAL18790 mgExact identifier — unii+route
186 equally ranked IID candidates
SUCROSESUCROSEC151H8M554SUSPENSION, EXTENDED RELEASE / ORAL5400 mgExact identifier — unii+route
186 equally ranked IID candidates
SODIUM THIOSULFATESODIUM THIOSULFATEHX1032V43MTABLET / ORAL3 mgExact identifier — unii+route
24 equally ranked IID candidates
SUCROSESUCROSEC151H8M554TABLET, COATED / ORAL516.42 mgExact identifier — unii+route
186 equally ranked IID candidates
SUCROSESUCROSEC151H8M554CONCENTRATE / ORAL4800 mgExact identifier — unii+route
186 equally ranked IID candidates
SUCROSESUCROSEC151H8M554POWDER / ORAL27768 mgExact identifier — unii+route
186 equally ranked IID candidates
SUCROSESUCROSEC151H8M554TABLET, DELAYED RELEASE / ORAL295.33 mgExact identifier — unii+route
186 equally ranked IID candidates
SUCROSESUCROSEC151H8M554TABLET, CHEWABLE / ORAL7258 mgExact identifier — unii+route
186 equally ranked IID candidates
SUCROSESUCROSEC151H8M554TABLET, EXTENDED RELEASE / ORAL284.54 mgExact identifier — unii+route
186 equally ranked IID candidates
SUCROSESUCROSEC151H8M554DROPS / ORALNAExact identifier — unii+route
186 equally ranked IID candidates
SUCROSESUCROSEC151H8M554SUSPENSION / ORAL48209 mgExact identifier — unii+route
186 equally ranked IID candidates
SUCROSESUCROSEC151H8M554CAPSULE, DELAYED RELEASE / ORAL955 mgExact identifier — unii+route
186 equally ranked IID candidates
SUCROSESUCROSEC151H8M554CAPSULE, COATED, EXTENDED RELEASE / ORAL86 mgExact identifier — unii+route
186 equally ranked IID candidates
SUCROSESUCROSEC151H8M554ELIXIR / ORAL18000 mgExact identifier — unii+route
186 equally ranked IID candidates
SUCROSESUCROSEC151H8M554CAPSULE, DELAYED RELEASE / ORAL955 mgExact identifier — unii+route
186 equally ranked IID candidates
SUCROSESUCROSEC151H8M554CAPSULE / ORAL3568 mgExact identifier — unii+route
186 equally ranked IID candidates
SUCROSESUCROSEC151H8M554TABLET, FILM COATED / ORAL145 mgExact identifier — unii+route
186 equally ranked IID candidates
SUCROSESUCROSEC151H8M554POWDER, FOR SUSPENSION / ORAL40017 mgExact identifier — unii+route
186 equally ranked IID candidates
SODIUM THIOSULFATESODIUM THIOSULFATEHX1032V43MSOLUTION / ORAL22 mg/1mlExact identifier — unii+route
24 equally ranked IID candidates
SUCROSESUCROSEC151H8M554GRANULE, FOR SUSPENSION / ORAL31885 mgExact identifier — unii+route
186 equally ranked IID candidates
SUCROSESUCROSEC151H8M554SUSPENSION / ORAL48209 mgExact identifier — unii+route
186 equally ranked IID candidates
SUCROSESUCROSEC151H8M554DROPS / ORALNAExact identifier — unii+route
186 equally ranked IID candidates
SODIUM THIOSULFATESODIUM THIOSULFATEHX1032V43MTABLET / ORAL3 mgExact identifier — unii+route
24 equally ranked IID candidates
SUCROSESUCROSEC151H8M554GRANULE, FOR SUSPENSION / ORAL31885 mgExact identifier — unii+route
186 equally ranked IID candidates
SUCROSESUCROSEC151H8M554GRANULE, FOR SUSPENSION, EXTENDED RELEASE / ORAL18790 mgExact identifier — unii+route
186 equally ranked IID candidates
SUCROSESUCROSEC151H8M554WAFER / ORAL155.2 mgExact identifier — unii+route
186 equally ranked IID candidates
SUCROSESUCROSEC151H8M554GRANULE, FOR SOLUTION / ORAL42596 mgExact identifier — unii+route
186 equally ranked IID candidates
SUCROSESUCROSEC151H8M554WAFER / ORAL155.2 mgExact identifier — unii+route
186 equally ranked IID candidates
SUCROSESUCROSEC151H8M554CAPSULE, COATED PELLETS / ORAL59.8 mgExact identifier — unii+route
186 equally ranked IID candidates
SUCROSESUCROSEC151H8M554POWDER, FOR SOLUTION / ORAL38666 mgExact identifier — unii+route
186 equally ranked IID candidates
SUCROSESUCROSEC151H8M554GRANULE, FOR SUSPENSION, EXTENDED RELEASE / ORAL18790 mgExact identifier — unii+route
186 equally ranked IID candidates
SODIUM THIOSULFATESODIUM THIOSULFATEHX1032V43MCAPSULE / ORAL20 mgExact identifier — unii+route
24 equally ranked IID candidates
SUCROSESUCROSEC151H8M554POWDER, FOR SOLUTION / ORAL38666 mgExact identifier — unii+route
186 equally ranked IID candidates
SUCROSESUCROSEC151H8M554TABLET, FILM COATED / ORAL145 mgExact identifier — unii+route
186 equally ranked IID candidates
SUCROSESUCROSEC151H8M554TABLET, FILM COATED / ORAL145 mgExact identifier — unii+route
186 equally ranked IID candidates
SUCROSESUCROSEC151H8M554TROCHE / ORALNAExact identifier — unii+route
186 equally ranked IID candidates
SUCROSESUCROSEC151H8M554GRANULE, FOR SUSPENSION, EXTENDED RELEASE / ORAL18790 mgExact identifier — unii+route
186 equally ranked IID candidates
SUCROSESUCROSEC151H8M554TABLET / ORAL4249 mgExact identifier — unii+route
186 equally ranked IID candidates
SUCROSESUCROSEC151H8M554CONCENTRATE / ORAL4800 mgExact identifier — unii+route
186 equally ranked IID candidates
SUCROSESUCROSEC151H8M554SYRUP / ORAL46400 mgExact identifier — unii+route
186 equally ranked IID candidates
SUCROSESUCROSEC151H8M554LIQUID / ORAL37500 mgExact identifier — unii+route
186 equally ranked IID candidates
SODIUM THIOSULFATESODIUM THIOSULFATEHX1032V43MCAPSULE / ORAL20 mgExact identifier — unii+route
24 equally ranked IID candidates
SUCROSESUCROSEC151H8M554TABLET, DELAYED RELEASE / ORAL295.33 mgExact identifier — unii+route
186 equally ranked IID candidates
SUCROSESUCROSEC151H8M554SYRUP / ORAL46400 mgExact identifier — unii+route
186 equally ranked IID candidates
SUCROSESUCROSEC151H8M554SOLUTION / ORAL70000 mgExact identifier — unii+route
186 equally ranked IID candidates
SUCROSESUCROSEC151H8M554TABLET, FILM COATED / ORAL145 mgExact identifier — unii+route
186 equally ranked IID candidates
SUCROSESUCROSEC151H8M554GRANULE, FOR SOLUTION / ORAL42596 mgExact identifier — unii+route
186 equally ranked IID candidates
SUCROSESUCROSEC151H8M554TABLET, COATED / ORAL516.42 mgExact identifier — unii+route
186 equally ranked IID candidates
SUCROSESUCROSEC151H8M554DROPS / ORALNAExact identifier — unii+route
186 equally ranked IID candidates
SODIUM THIOSULFATESODIUM THIOSULFATEHX1032V43MTABLET / ORAL3 mgExact identifier — unii+route
24 equally ranked IID candidates
SODIUM THIOSULFATESODIUM THIOSULFATEHX1032V43MSOLUTION/ DROPS / ORAL0.5 mg/1mlExact identifier — unii+route
24 equally ranked IID candidates
SUCROSESUCROSEC151H8M554SYRUP / ORAL46400 mgExact identifier — unii+route
186 equally ranked IID candidates
SUCROSESUCROSEC151H8M554SUSPENSION/ DROPS / ORAL3750 mgExact identifier — unii+route
186 equally ranked IID candidates
SUCROSESUCROSEC151H8M554TABLET, FILM COATED, EXTENDED RELEASE / ORAL119.12 mgExact identifier — unii+route
186 equally ranked IID candidates
SUCROSESUCROSEC151H8M554GRANULE, FOR SOLUTION / ORAL42596 mgExact identifier — unii+route
186 equally ranked IID candidates
SUCROSESUCROSEC151H8M554CAPSULE, EXTENDED RELEASE / ORAL619 mgExact identifier — unii+route
186 equally ranked IID candidates
SUCROSESUCROSEC151H8M554POWDER, FOR SUSPENSION / ORAL40017 mgExact identifier — unii+route
186 equally ranked IID candidates
SUCROSESUCROSEC151H8M554CAPSULE / ORAL3568 mgExact identifier — unii+route
186 equally ranked IID candidates
SUCROSESUCROSEC151H8M554TABLET, CHEWABLE / ORAL7258 mgExact identifier — unii+route
186 equally ranked IID candidates

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 45.

Orange Book products#

Current product rows page 1 of 1 · 3 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
N018671-001SODIUM IODIDE I 123SODIUM IODIDE I-123100uCiCAPSULE / ORALAARLD, RS1982-05-27
N018671-002SODIUM IODIDE I 123SODIUM IODIDE I-123200uCiCAPSULE / ORALAARLD, RS1982-05-27
N018671-003SODIUM IODIDE I 123SODIUM IODIDE I-123400uCiCAPSULE / ORAL1982-05-27

Therapeutic equivalence codes#

Current TE-code rows page 1 of 1 · 2 matching rows.

Application-product, TE code table
Application-productTE code
N018671-001AA
N018671-002AA

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 4 · 135 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-11-14 07:37:172026-10N018671-001SODIUM IODIDE I 123100uCiCAPSULE / ORALAARLD, RS1982-05-27d4dbc9d85df4…
2026-11-14 07:37:172026-10N018671-002SODIUM IODIDE I 123200uCiCAPSULE / ORALAARLD, RS1982-05-27d4dbc9d85df4…
2026-11-14 07:37:172026-10N018671-003SODIUM IODIDE I 123400uCiCAPSULE / ORAL1982-05-27d4dbc9d85df4…
2026-10-15 13:18:302026-09N018671-001SODIUM IODIDE I 123100uCiCAPSULE / ORALAARLD, RS1982-05-27c2088c7a36db…
2026-10-15 13:18:302026-09N018671-002SODIUM IODIDE I 123200uCiCAPSULE / ORALAARLD, RS1982-05-27c2088c7a36db…
2026-10-15 13:18:302026-09N018671-003SODIUM IODIDE I 123400uCiCAPSULE / ORAL1982-05-27c2088c7a36db…
2026-09-14 22:38:342026-08N018671-001SODIUM IODIDE I 123100uCiCAPSULE / ORALAARLD, RS1982-05-2784e616aacf4f…
2026-09-14 22:38:342026-08N018671-002SODIUM IODIDE I 123200uCiCAPSULE / ORALAARLD, RS1982-05-2784e616aacf4f…
2026-09-14 22:38:342026-08N018671-003SODIUM IODIDE I 123400uCiCAPSULE / ORAL1982-05-2784e616aacf4f…
2026-08-18 06:07:402026-07N018671-001SODIUM IODIDE I 123100uCiCAPSULE / ORALAARLD, RS1982-05-27caaa826d4ba7…
2026-08-18 06:07:402026-07N018671-002SODIUM IODIDE I 123200uCiCAPSULE / ORALAARLD, RS1982-05-27caaa826d4ba7…
2026-08-18 06:07:402026-07N018671-003SODIUM IODIDE I 123400uCiCAPSULE / ORAL1982-05-27caaa826d4ba7…
2026-02-19 14:30 UTC2026-02N018671-001SODIUM IODIDE I 123100uCiCAPSULE / ORALAARLD, RS1982-05-27011fe1cb6892…
2026-02-19 14:30 UTC2026-02N018671-002SODIUM IODIDE I 123200uCiCAPSULE / ORALAARLD, RS1982-05-27011fe1cb6892…
2026-02-19 14:30 UTC2026-02N018671-003SODIUM IODIDE I 123400uCiCAPSULE / ORAL1982-05-27011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N018671-001SODIUM IODIDE I 123100uCiCAPSULE / ORALAARLD, RS1982-05-2731067a03dcf5…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N018671-002SODIUM IODIDE I 123200uCiCAPSULE / ORALAARLD, RS1982-05-2731067a03dcf5…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N018671-003SODIUM IODIDE I 123400uCiCAPSULE / ORAL1982-05-2731067a03dcf5…
2025-08-23 18:47 UTC2025-08N018671-001SODIUM IODIDE I 123100uCiCAPSULE / ORALAARLD, RS1982-05-276a471c1ec25d…
2025-08-23 18:47 UTC2025-08N018671-002SODIUM IODIDE I 123200uCiCAPSULE / ORALAARLD, RS1982-05-276a471c1ec25d…
2025-08-23 18:47 UTC2025-08N018671-003SODIUM IODIDE I 123400uCiCAPSULE / ORAL1982-05-276a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N018671-001SODIUM IODIDE I 123100uCiCAPSULE / ORALAARLD, RS1982-05-27fd3edfee7708…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N018671-002SODIUM IODIDE I 123200uCiCAPSULE / ORALAARLD, RS1982-05-27fd3edfee7708…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N018671-003SODIUM IODIDE I 123400uCiCAPSULE / ORAL1982-05-27fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02N018671-001SODIUM IODIDE I 123100uCiCAPSULE / ORALAARLD, RS1982-05-27b8a1b40f171c…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02N018671-002SODIUM IODIDE I 123200uCiCAPSULE / ORALAARLD, RS1982-05-27b8a1b40f171c…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02N018671-003SODIUM IODIDE I 123400uCiCAPSULE / ORAL1982-05-27b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01N018671-001SODIUM IODIDE I 123100uCiCAPSULE / ORALAARLD, RS1982-05-2703ed91905a0d…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01N018671-002SODIUM IODIDE I 123200uCiCAPSULE / ORALAARLD, RS1982-05-2703ed91905a0d…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01N018671-003SODIUM IODIDE I 123400uCiCAPSULE / ORAL1982-05-2703ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12N018671-001SODIUM IODIDE I 123100uCiCAPSULE / ORALAARLD, RS1982-05-272680178bc6a6…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12N018671-002SODIUM IODIDE I 123200uCiCAPSULE / ORALAARLD, RS1982-05-272680178bc6a6…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12N018671-003SODIUM IODIDE I 123400uCiCAPSULE / ORAL1982-05-272680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09N018671-001SODIUM IODIDE I 123100uCiCAPSULE / ORALAARLD, RS1982-05-275bbf6a4d5a75…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09N018671-002SODIUM IODIDE I 123200uCiCAPSULE / ORALAARLD, RS1982-05-275bbf6a4d5a75…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09N018671-003SODIUM IODIDE I 123400uCiCAPSULE / ORAL1982-05-275bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11N018671-001SODIUM IODIDE I 123100uCiCAPSULE / ORALAARLD, RS1982-05-27d8e5a09893c0…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11N018671-002SODIUM IODIDE I 123200uCiCAPSULE / ORALAARLD, RS1982-05-27d8e5a09893c0…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11N018671-003SODIUM IODIDE I 123400uCiCAPSULE / ORAL1982-05-27d8e5a09893c0…
2024-10-29 15:01 UTC2024-10N018671-001SODIUM IODIDE I 123100uCiCAPSULE / ORALAARLD, RS1982-05-27d06236e962d9…

Observed Orange Book normalized TE history#

Normalized TE history page 1 of 3 · 90 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2026-11-14 07:37:172026-10N018671-001AA1d4dbc9d85df4…
2026-11-14 07:37:172026-10N018671-002AA1d4dbc9d85df4…
2026-10-15 13:18:302026-09N018671-001AA1c2088c7a36db…
2026-10-15 13:18:302026-09N018671-002AA1c2088c7a36db…
2026-09-14 22:38:342026-08N018671-001AA184e616aacf4f…
2026-09-14 22:38:342026-08N018671-002AA184e616aacf4f…
2026-08-18 06:07:402026-07N018671-001AA1caaa826d4ba7…
2026-08-18 06:07:402026-07N018671-002AA1caaa826d4ba7…
2026-02-19 14:30 UTC2026-02N018671-001AA1011fe1cb6892…
2026-02-19 14:30 UTC2026-02N018671-002AA1011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N018671-001AA131067a03dcf5…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N018671-002AA131067a03dcf5…
2025-08-23 18:47 UTC2025-08N018671-001AA16a471c1ec25d…
2025-08-23 18:47 UTC2025-08N018671-002AA16a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N018671-001AA1fd3edfee7708…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N018671-002AA1fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02N018671-001AA1b8a1b40f171c…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02N018671-002AA1b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01N018671-001AA103ed91905a0d…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01N018671-002AA103ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12N018671-001AA12680178bc6a6…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12N018671-002AA12680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09N018671-001AA15bbf6a4d5a75…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09N018671-002AA15bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11N018671-001AA1d8e5a09893c0…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11N018671-002AA1d8e5a09893c0…
2024-10-29 15:01 UTC2024-10N018671-001AA1d06236e962d9…
2024-10-29 15:01 UTC2024-10N018671-002AA1d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08N018671-001AA179d66fd596c7…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08N018671-002AA179d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07N018671-001AA1301d65b070ca…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07N018671-002AA1301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06N018671-001AA11e350fbaab3a…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06N018671-002AA11e350fbaab3a…
2024-05-31 18:47 UTC2024-05N018671-001AA18072bd15b7f6…
2024-05-31 18:47 UTC2024-05N018671-002AA18072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06N018671-001AA15c6f7cd8ea54…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06N018671-002AA15c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04N018671-001AA15d02ea3f76ae…
2022-04-08 23:34 UTC2022-04N018671-002AA15d02ea3f76ae…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
Sodium Iodide I 123SODIUM IODIDE I 123Cardinal Health 418, Inc50415c27-1928-4307-b1dc-648f47edf65d2018-04-17Warnings, Adverse reactionsExact identifier
ndc (package): 48815-1002-1
ndc (package): 48815-1001-5
ndc (package): 48815-1001-1
ndc (package): 48815-1002-5
ndc (product): 48815-1002
ndc (product): 48815-1001
ndc11 (package): 48815100205
ndc11 (package): 48815100201
ndc11 (package): 48815100101
ndc11 (package): 48815100105
spl id: c07d2306-68cc-4c33-9b6f-4750c0edf625
spl set id: 50415c27-1928-4307-b1dc-648f47edf65d

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.